MENS Stock Analysis: Buy, Sell, or Hold?
MENS - Jyong Biotech Ltd. Ordinary Shares
$2.18
0.15 (7.39%)
â˛
5d:
+7.39%
30d:
-3.11%
90d:
-0.91%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When MENS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: MENS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: MENS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: MENS is currently trading at $2.18, which is considered fair relative to its 30-day fair value range of $2.04 to $2.27.
Technical Outlook: Technically, MENS is showing sideways momentum. Immediate support is located at $1.92, while resistance sits at $2.40. The stock is showing strong short-term momentum, up 7.4% recently.
Market Sentiment: MENS scores 73/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MENS is showing sideways momentum. Immediate support is located at $1.92, while resistance sits at $2.40. The stock is showing strong short-term momentum, up 7.4% recently.
Market Sentiment: MENS scores 73/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.04 -
$2.27
Company Quality Score
53/100
(HOLD)
Options IV Signal
100th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
70.5%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Options expensive (IV 100th percentile)
- BULLISH: Strong technical setup (73/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.4%)
- WARNING: Composite score 52/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.04 -
$2.27
Current vs Trading Range
FAIR
Expected Move (7 Days)
Âą$0.60
(27.6%)
Support & Resistance Levels
Support Level
$1.92
Resistance Level
$2.40
Current Trend
Sideways
Technical data as of
Oct 2, 2026
Fundamental Context
Share & Embed Analysis
Last updated: October 03, 2026 4:02 AM ET
Data refreshes hourly during market hours. Next update: 5:02 AM
Data refreshes hourly during market hours. Next update: 5:02 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MENS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |